These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 24295730)
1. Ontogenetic manganese exposure with perinatal 6-OHDA lesioning alters behavioral responses of rats to dopamine D₁ and D2 agonist treatments. Szkilnik R; Brus R; Malinowska-Borowska J; Nowak D; Waliczek M; Kostrzewa RM; Nowak P Environ Toxicol Pharmacol; 2014 Jan; 37(1):28-36. PubMed ID: 24295730 [TBL] [Abstract][Full Text] [Related]
2. Ontogenetic exposure of rats to pre- and post-natal manganese enhances behavioral impairments produced by perinatal 6-hydroxydopamine. Nowak P; Bojanek K; Szkilnik R; Jośko J; Boroń D; Adwent M; Gorczyca P; Kostrzewa RM; Brus R Neurotox Res; 2011 May; 19(4):536-43. PubMed ID: 20369314 [TBL] [Abstract][Full Text] [Related]
3. Effect of pre- and postnatal manganese exposure on brain histamine content in a rodent model of Parkinson's disease. Brus R; Jochem J; Nowak P; Adwent M; Boroń D; Brus H; Kostrzewa RM Neurotox Res; 2012 Feb; 21(2):143-8. PubMed ID: 21822760 [TBL] [Abstract][Full Text] [Related]
4. Ontogenetic quinpirole treatments fail to prime for D2 agonist-enhancement of locomotor activity in 6-hydroxydopamine-lesioned rats. Brus R; Kostrzewa RM; Nowak P; Perry KW; Kostrzewa JP Neurotox Res; 2003; 5(5):329-38. PubMed ID: 14715452 [TBL] [Abstract][Full Text] [Related]
5. p-Chloroamphetamine-Enhanced Neostriatal Dopamine Exocytosis in Rats Neonatally Co-lesioned with 6-OHDA and 5,7-DHT: Relevance to Parkinson's Disease. Kostrzewa JP; Kostrzewa RM Neurotox Res; 2020 Mar; 37(3):543-552. PubMed ID: 31939043 [TBL] [Abstract][Full Text] [Related]
6. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation. Hu XT; White FJ Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677 [TBL] [Abstract][Full Text] [Related]
7. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Henry B; Crossman AR; Brotchie JM Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296 [TBL] [Abstract][Full Text] [Related]
8. Effect of prenatal manganese intoxication on [(3)H]glucose uptake in the brain of rats lesioned as neonates with 6-hydroxydopamine. Kwieciński A; Nowak P Pharmacol Rep; 2009; 61(3):558-63. PubMed ID: 19605956 [TBL] [Abstract][Full Text] [Related]
9. Perinatal manganese exposure and hydroxyl radical formation in rat brain. Bałasz M; Szkilnik R; Brus R; Malinowska-Borowska J; Kasperczyk S; Nowak D; Kostrzewa RM; Nowak P Neurotox Res; 2015 Jan; 27(1):1-14. PubMed ID: 25323423 [TBL] [Abstract][Full Text] [Related]
10. Histaminergic activity in a rodent model of Parkinson's disease. Nowak P; Noras L; Jochem J; Szkilnik R; Brus H; Körossy E; Drab J; Kostrzewa RM; Brus R Neurotox Res; 2009 Apr; 15(3):246-51. PubMed ID: 19384597 [TBL] [Abstract][Full Text] [Related]
11. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development. Neal-Beliveau BS; Joyce JN Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220 [TBL] [Abstract][Full Text] [Related]
12. D1 priming enhances both D1- and D2-mediated rotational behavior and striatal Fos expression in 6-hydroxydopamine lesioned rats. Pollack AE; Thomas LI Pharmacol Biochem Behav; 2010 Jan; 94(3):346-51. PubMed ID: 19800912 [TBL] [Abstract][Full Text] [Related]
13. Evidence for involvement of brain dopamine and other mechanisms in the behavioral action of the N-methyl-D-aspartic acid antagonist MK-801 in control and 6-hydroxydopamine-lesioned rats. Criswell HE; Johnson KB; Mueller RA; Breese GR J Pharmacol Exp Ther; 1993 May; 265(2):1001-10. PubMed ID: 8098756 [TBL] [Abstract][Full Text] [Related]
14. Substantia nigra glutamate antagonists produce contralateral turning and basal ganglia Fos expression: interactions with D1 and D2 dopamine receptor agonists. McPherson RJ; Marshall JF Synapse; 2000 Jun; 36(3):194-204. PubMed ID: 10819899 [TBL] [Abstract][Full Text] [Related]
15. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422 [TBL] [Abstract][Full Text] [Related]
16. Attenuation by Nardostachys jatamansi of 6-hydroxydopamine-induced parkinsonism in rats: behavioral, neurochemical, and immunohistochemical studies. Ahmad M; Yousuf S; Khan MB; Hoda MN; Ahmad AS; Ansari MA; Ishrat T; Agrawal AK; Islam F Pharmacol Biochem Behav; 2006 Jan; 83(1):150-60. PubMed ID: 16500697 [TBL] [Abstract][Full Text] [Related]
17. Neurochemical and behavioral responses to cocaine in adult male rats with neonatal isolation experience. Kosten TA; Zhang XY; Kehoe P J Pharmacol Exp Ther; 2005 Aug; 314(2):661-7. PubMed ID: 15845857 [TBL] [Abstract][Full Text] [Related]
18. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease. Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597 [TBL] [Abstract][Full Text] [Related]